Currently, there are 5.32M common shares owned by the public and among those 5.19M shares have been available to trade.
The company’s stock has a 5-day price change of -8.18% and 68.54% over the past three months. LPCN shares are trading 157.35% year to date (YTD), with the 12-month market performance up to 48.04% higher. It has a 12-month low price of $2.31 and touched a high of $10.85 over the same period. LPCN has an average intraday trading volume of 74.27K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.84%, 18.03%, and 78.19% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Lipocine Inc (NASDAQ: LPCN) shares accounts for 8.94% of the company’s 5.32M shares outstanding.
It has a market capitalization of $38.41M and a beta (3y monthly) value of 1.17. The earnings-per-share (ttm) stands at -$1.72. Price movements for the stock have been influenced by the stock’s volatility, which stands at 25.94% over the week and 10.89% over the month.
Earnings per share for the fiscal year are expected to increase by 68.15%, and 94.00% over the next financial year.
Looking at the support for the LPCN, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on June 24, 2021, with the firm’s price target at $3. Ladenburg Thalmann coverage for the Lipocine Inc (LPCN) stock in a research note released on December 10, 2020 offered a Buy rating with a price target of $3. H.C. Wainwright was of a view on January 12, 2018 that the stock is Buy, while Canaccord Genuity gave the stock Hold rating on January 11, 2018, issuing a price target of $11- $2. H.C. Wainwright on their part issued Buy rating on December 08, 2017.
